Swedish Company Astrazeneca Will Buy Biotechnology From Teneo Two:
To expand its blood cancer portfolio, Swedish Company AstraZeneca Will Buy Biotechnology From Teneo Two, which will be worth €1.22 billion. The pharmaceutical company AstraZeneca announced this statement on Tuesday. According to a statement from AstraZeneca, the agreement also provides the US-based Company’s investigational treatments for a specific non-Hodgkin lymphoma. This prospective new treatment for…
